ME02891B - Heterociklično amidno jedi njenje sirćetne kiseline - Google Patents
Heterociklično amidno jedi njenje sirćetne kiselineInfo
- Publication number
- ME02891B ME02891B MEP-2017-277A MEP2017277A ME02891B ME 02891 B ME02891 B ME 02891B ME P2017277 A MEP2017277 A ME P2017277A ME 02891 B ME02891 B ME 02891B
- Authority
- ME
- Montenegro
- Prior art keywords
- alkyl
- compound
- methyl
- disease
- halo
- Prior art date
Links
- -1 Heterocyclic acetic acid amide compound Chemical class 0.000 title claims 4
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000028698 Cognitive impairment Diseases 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- VJQUDVMFPHFRIP-UHFFFAOYSA-N 2-(5-chloro-2-oxo-1,3-benzoxazol-3-yl)-N-methyl-N-[[6-(trifluoromethyl)-1H-benzimidazol-2-yl]methyl]acetamide hydrochloride Chemical compound Cl.CN(Cc1nc2cc(ccc2[nH]1)C(F)(F)F)C(=O)Cn1c2cc(Cl)ccc2oc1=O VJQUDVMFPHFRIP-UHFFFAOYSA-N 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 102000015554 Dopamine receptor Human genes 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 claims 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- KXBGCNKQOGPHJY-UHFFFAOYSA-N n-[(6-chloro-1h-benzimidazol-2-yl)methyl]-n-methyl-2-[2-oxo-5-(trifluoromethyl)-1,3-benzoxazol-3-yl]acetamide Chemical compound C12=CC(C(F)(F)F)=CC=C2OC(=O)N1CC(=O)N(C)CC1=NC2=CC=C(Cl)C=C2N1 KXBGCNKQOGPHJY-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Claims (16)
1. Jedinjenje sa formulom (l) ili njegova so: (I) (gde prsten A je benzenov prsten, R1 je C1-6 alkil, halogen, halogeno-C1-6 alkil, ili -0-halogeno-C1-6 alkil, R2je H ili halogen, R R R11, R12, R13 i R14 su isti ili različiti jedan od drugog, i oni su H, cl-6 alkil, halogen, halogeno-Cl- 6 alkil, cikloalkil, -O-C1-6 alkil, ili -O-halogeno-C1-6 alkil, U je NR 1s ili O, V je CH ili N, u slučaju gde U je O, V je N, R15 je H, Cl-6 alkil, ili -Cl-6 alkilen-OH, i X je 0).
2.Jedinjenje ili njegova so u skladu sa patentnim zahtevom l, gde 1 U J.e NRIS, . V jeN.
3.Jedinjenje ili njegova so u skladu sa patentnim zahtevom 2, gde 13 R 1 je halogen, halogeno-C1 -6 alkil, ili -O-halogeno-C1-6 alkil, i , R R 11 12, R , i R 14 su isti ili različiti jedan od drugog, i oni su H, halogen, halogeno-C1-6 alkil, cikloalkil, ili -O-halogeno-C1-6 alkil.
4.Jedinjenje ili njegova so u skladu sa patentnim zahtevom 3, gde R 1s je H.
5.Jedinjenje ili nJegova so u skladu sa patentnim zahtevom 4, gde R 1 je halogen ili halogeno-C 1•6 alkil.
6., R , Jedinjenje ili njegova so u skladu sa patentnim zahtevom 5, gde R 11 12 R 13 i R 14 su isti ili različiti jedan od drugog, i oni su H, halogen, ili halogeno-C1.6 alkil.
7.Jedinjenje ili njegova so u skladu sa patentnim zahtevom 6, gde R 12 je halogen ili , halogeno-C 1-6 alkil, i R 11 R 13 i R 14 su H.
8.Jedinjenje ili njegova so u skladu sa patentnim zahtevom 7, koje je odabrano od sledeće grupe koja se sastoji od: 2-(5-hloro-2-okso-1,3-benzoksazol-3(2H)-ii)-N-metil-N-{[5-(trifluorometil)- l H-benzimidazol-2- il]metil acetamid, N-[(5-hloro-1H-benzimidazol-2-il)metil]-2-(5-hloro-2-okso-1,3-benzoksazol-3(2H)-il)-N metilacetamid, 2-(5-hloro-4-fluoro-2-okso-1,3-benzoksazol-3(2H)-ii)-N-metii-N-{[5-(trifluorometil)-1H benzimidazo1-2-il]metil}acetamid, N-[(5-bromo-1H-benzimidazol-2-il)metil]-2-(5-hloro-2-okso-1,3-benzoksazol-3(2H)-il)-N metilacetamid, i N-[(5-hloro-1H-benzimidazol-2-il)metii]-N-metil-2-[2-okso-5-(trifluorometil)-1,3-benzoksazol- 3(2H)-il]acetamid.
9. Jedinjenje ili njegova so u skladu sa patentnim zahtevom 8, koje je 2-(5-hloro-2-okso- 1,3-benzoksazol-3(2H)-il)-N-metii-N-{[5-(trifluorometil)-1H-benzimidazol-2-il]metil} acetamid hidrohlorid.
10.Jedinjenje ili njegova so u skladu sa patentnim zahtevom 8, koje je 2-(5-hloro-4-fluoro-2- okso-1,3-benzoksazol-3(2H)-ii)-N-metii-N-{[5-(trifluorometil)-1H-benzimidazol-2- il]metil}acetamid.
11. Jedinjenje ili njegova so u skladu sa patentnim zahtevom 8, koje je N-[(5-bromo-lH benzimidazol-2-il)metil]-2-(5-hloro-2-okso-1,3-benzoksazol-3(2H)-ii)-N-metilacetamid.
12. Farmaceutska kompozicija koja sadrži jedinjenje ili njegovu so u skladu sa patentnim zahtevom l, i farmaceutski prihvatljiv ekscipijens.
13. Farmaceutska kompozicija u skladu sa patentnim zahtevom 12, koja je pozitivni alostemi modulator dopaminskog receptora D l.
14. Farmaceutska kompozicija u skladu sa patentnim zahtevom 12, za primenu u prevenciji ili lečenju bolesti koja je odabrana od grupe koja se sastoji od kognitivnog oštećenja, negativnih simptoma šizofrenije, Parkinsonove bolesti, Alchajmerove bolesti, Hantingtonove bolesti, i zavisnosti od lekova.
15. Primena jedinjenja ili njegove soli u skladu sa patentnim zahtevom l za proizvodnju farmaceutske kompozicije za sprečavanje ili lečenje bolesti koja je odabrana od grupe koja se sastoji od kognitivnog oštećenja, negativnih simptoma šizofrenije, Parkinsonove bolesti, Alchajmerove bolesti, Hantingtonove bolesti, i zavisnosti od lekova.
16. Jedinjenje ili njegova so u skladu sa patentnim zahtevom l za primenu u metodi za sprečavanje ili lečenje bolesti koja je odabrana od grupe koja se sastoji od kognitivnog oštećenja, negativnih simptoma šizofrenije, Parkinsonove bolesti, Alchajmerove bolesti, Hantingtonove bolesti, i zavisnosti od lekova.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013087151 | 2013-04-18 | ||
| PCT/JP2014/061007 WO2014171528A1 (ja) | 2013-04-18 | 2014-04-18 | ヘテロ環酢酸アミド化合物 |
| EP14786115.7A EP2987793B1 (en) | 2013-04-18 | 2014-04-18 | Heterocyclic acetic acid amide compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02891B true ME02891B (me) | 2018-04-20 |
Family
ID=51729480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-277A ME02891B (me) | 2013-04-18 | 2014-04-18 | Heterociklično amidno jedi njenje sirćetne kiseline |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US8937087B2 (me) |
| EP (1) | EP2987793B1 (me) |
| JP (1) | JP6252582B2 (me) |
| KR (1) | KR102193247B1 (me) |
| CN (1) | CN105121435B (me) |
| AR (1) | AR095883A1 (me) |
| AU (1) | AU2014254768B2 (me) |
| BR (1) | BR112015026512B1 (me) |
| CA (1) | CA2909783C (me) |
| CY (1) | CY1119754T1 (me) |
| DK (1) | DK2987793T3 (me) |
| EA (1) | EA028968B1 (me) |
| ES (1) | ES2651866T3 (me) |
| HR (1) | HRP20171786T1 (me) |
| HU (1) | HUE036054T2 (me) |
| IL (1) | IL241962B (me) |
| LT (1) | LT2987793T (me) |
| ME (1) | ME02891B (me) |
| MX (1) | MX2015014646A (me) |
| MY (1) | MY175971A (me) |
| NO (1) | NO2987793T3 (me) |
| NZ (1) | NZ713118A (me) |
| PH (1) | PH12015502341B1 (me) |
| PL (1) | PL2987793T3 (me) |
| PT (1) | PT2987793T (me) |
| RS (1) | RS56865B1 (me) |
| SA (1) | SA515370015B1 (me) |
| SG (1) | SG11201508448RA (me) |
| SI (1) | SI2987793T1 (me) |
| SM (1) | SMT201700594T1 (me) |
| TW (1) | TWI625329B (me) |
| UA (1) | UA116243C2 (me) |
| WO (1) | WO2014171528A1 (me) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR105025A1 (es) | 2015-06-19 | 2017-08-30 | Astellas Pharma Inc | Compuesto de imidazodiazepina |
| TWI725408B (zh) | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
| AU2019339186A1 (en) | 2018-09-13 | 2021-03-25 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
| CN110590576A (zh) * | 2019-08-15 | 2019-12-20 | 安徽金禾实业股份有限公司 | 一种4-多氟代甲氧基邻苯二胺的制备方法 |
| CN114380709B (zh) * | 2021-12-31 | 2023-07-21 | 西北农林科技大学 | 4-氯-2-酰氨基酚的合成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2674524B1 (fr) * | 1991-03-25 | 1993-05-21 | Adir | Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| EP1165557B1 (en) * | 1999-04-02 | 2004-09-29 | Neurogen Corporation | ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS |
| US6380210B1 (en) | 1999-04-02 | 2002-04-30 | Neurogen Corporation | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
| US6627624B1 (en) | 1999-04-02 | 2003-09-30 | Neurogen Corporation | Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
| AUPQ309399A0 (en) | 1999-09-28 | 1999-10-21 | Fujisawa Pharmaceutical Co., Ltd. | Benzothiazoline derivatives |
| EP1434765B1 (en) | 2001-09-14 | 2009-12-02 | High Point Pharmaceuticals, LLC | Substituted piperidines with selective binding to histamine h3-receptor |
| US7361671B2 (en) | 2001-11-15 | 2008-04-22 | The Institute For Pharmaceutical Discovery, Inc. | Substituted heteroarylalkanoic acids |
| EP1496838B1 (en) | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Substituted amides |
| US7202251B2 (en) | 2003-03-14 | 2007-04-10 | Merck & Co., Inc. | Bicyclic anilide spirohydantoin CGRP receptor antagonists |
| CN1922141A (zh) * | 2004-02-23 | 2007-02-28 | 大日本住友制药株式会社 | 新的杂环化合物 |
| ES2332597T3 (es) * | 2004-05-27 | 2010-02-09 | Ucb Pharma S.A. | Derivados de benzoxazolona, procedimientos para su preparacion y su uso. |
| US7790726B2 (en) | 2005-08-16 | 2010-09-07 | Chemocentryx, Inc. | Monocyclic and bicyclic compounds and methods of use |
| WO2007073432A2 (en) | 2005-10-11 | 2007-06-28 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
| CL2007002097A1 (es) * | 2006-07-20 | 2008-01-18 | Smithkline Beecham Corp | Compuestos derivados de pirrolidina o morfolina antagonistas de urotensina ii; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar insuficiencia cardiaca congestiva, insuficiencia cardiaca isquemica, angina, isquemia del miocardio, vejiga hiperactiva, asma y/o copd, entre otras. |
| US7786157B2 (en) | 2007-03-16 | 2010-08-31 | Chemocentryx, Inc. | OXO-imidazolidines as modulators of chemokine receptors |
| DE102007026341A1 (de) * | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
| GB0713686D0 (en) * | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
-
2014
- 2014-04-16 AR ARP140101624A patent/AR095883A1/es active IP Right Grant
- 2014-04-17 TW TW103114022A patent/TWI625329B/zh not_active IP Right Cessation
- 2014-04-18 AU AU2014254768A patent/AU2014254768B2/en not_active Ceased
- 2014-04-18 CA CA2909783A patent/CA2909783C/en active Active
- 2014-04-18 ES ES14786115.7T patent/ES2651866T3/es active Active
- 2014-04-18 MX MX2015014646A patent/MX2015014646A/es active IP Right Grant
- 2014-04-18 CN CN201480020846.XA patent/CN105121435B/zh active Active
- 2014-04-18 SM SM20170594T patent/SMT201700594T1/it unknown
- 2014-04-18 DK DK14786115.7T patent/DK2987793T3/en active
- 2014-04-18 EP EP14786115.7A patent/EP2987793B1/en active Active
- 2014-04-18 UA UAA201511337A patent/UA116243C2/uk unknown
- 2014-04-18 EA EA201591988A patent/EA028968B1/ru not_active IP Right Cessation
- 2014-04-18 US US14/256,135 patent/US8937087B2/en active Active
- 2014-04-18 WO PCT/JP2014/061007 patent/WO2014171528A1/ja not_active Ceased
- 2014-04-18 SI SI201430479T patent/SI2987793T1/en unknown
- 2014-04-18 PL PL14786115T patent/PL2987793T3/pl unknown
- 2014-04-18 JP JP2015512531A patent/JP6252582B2/ja active Active
- 2014-04-18 RS RS20171324A patent/RS56865B1/sr unknown
- 2014-04-18 HU HUE14786115A patent/HUE036054T2/hu unknown
- 2014-04-18 ME MEP-2017-277A patent/ME02891B/me unknown
- 2014-04-18 PT PT147861157T patent/PT2987793T/pt unknown
- 2014-04-18 LT LTEP14786115.7T patent/LT2987793T/lt unknown
- 2014-04-18 BR BR112015026512-0A patent/BR112015026512B1/pt not_active IP Right Cessation
- 2014-04-18 HR HRP20171786TT patent/HRP20171786T1/hr unknown
- 2014-04-18 KR KR1020157027691A patent/KR102193247B1/ko not_active Expired - Fee Related
- 2014-04-18 SG SG11201508448RA patent/SG11201508448RA/en unknown
- 2014-04-18 NZ NZ713118A patent/NZ713118A/en not_active IP Right Cessation
- 2014-04-18 NO NO14786115A patent/NO2987793T3/no unknown
- 2014-04-18 MY MYPI2015703694A patent/MY175971A/en unknown
- 2014-10-28 US US14/525,982 patent/US9708307B2/en active Active
-
2015
- 2015-10-07 IL IL241962A patent/IL241962B/en active IP Right Grant
- 2015-10-08 PH PH12015502341A patent/PH12015502341B1/en unknown
- 2015-10-18 SA SA515370015A patent/SA515370015B1/ar unknown
-
2017
- 2017-12-06 CY CY20171101288T patent/CY1119754T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02891B (me) | Heterociklično amidno jedi njenje sirćetne kiseline | |
| HRP20141108T1 (hr) | Antagonisti piperidinon karboksamid azaindan cgrp receptora | |
| JP2012224649A5 (me) | ||
| HRP20180341T1 (hr) | Derivati 6-(5-hidroksi-1h-pirazol-1-il)nikotinamida i njihova uporaba kao inhibitora phd | |
| RU2015128794A (ru) | Композиция перорально распадающейся таблетки, обеспечивающая повышенную биодоступность | |
| HRP20220003T1 (hr) | Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži | |
| MX2009003410A (es) | Fosfoindoles enantiomericamente puros como inhibidores de vih. | |
| HRP20161125T1 (hr) | Makrociklički purini za liječenje virusnih infekcija | |
| RU2006122599A (ru) | Способ изготовления твердого, орально применяемого фармацевтического состава | |
| FI3406609T3 (fi) | Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina | |
| PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
| PE20170004A1 (es) | Inhibidores de biaril cinasa | |
| JP2015501783A5 (me) | ||
| CL2012001133A1 (es) | Composicion farmaceutica oral que comprende ponatinib 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)-metil)-3-(trifluorometil)fenil)benzamida y al menos un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de neoplasma, cancer o un trastorno hiperproliferativo. | |
| PE20141372A1 (es) | Nuevos derivados dihidroquinolina-2-ona | |
| MD20140084A2 (en) | New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| HRP20151405T1 (hr) | Novi supstituirani kinolinski spojevi kao inhibitori reduktaze s-nitrosoglutationa | |
| JP2020529998A5 (me) | ||
| EP2985284A4 (en) | DICARBOXYLIC ACID BISAMID DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREFROM AND METHOD FOR THE PRODUCTION OF DICARBOXYLIC ACID BISAMID DERIVATIVES | |
| ME02606B (me) | Jedinjenja 1,3 - oksazolidina ili 1,3- oksazinana kao antagonisti oreksinskog receptora | |
| JP2013538206A5 (me) | ||
| JP2016537338A5 (me) | ||
| GB201302406D0 (en) | Controlled drug release | |
| MX2020002432A (es) | Composicion farmaceutica. | |
| PE20161415A1 (es) | Derivados de etinilo |